Ninety-Day Readmission Following Shoulder Arthroplasty

Abstract

Introduction: Hospital readmissions after elective shoulder arthroplasty represent a costly burden to the health-care system due to the rising demand for this procedure. Nevertheless, the reasons for readmissions remain inconclusive. Therefore, the main purposes of the current investigation were to determine (1) the readmission rates within 90 days after shoulder arthroplasty, (2) the reasons behind those readmissions, and (3) the characteristics of readmitted patients. Methods: A retrospective review was performed on 184 patients who underwent total shoulder arthroplasty (TSA) or reverse shoulder arthroplasty (RSA) performed by a single surgeon at a single institution between 2010 and 2016. The readmissions that occurred within 90 days after surgery and their reasons were noted. Patient characteristics were compared between readmitted and non-readmitted patients. Results: Overall, 7.1% of patients were readmitted within 90 days after shoulder arthroplasty. However, patients with a previous surgery on the same shoulder of the TSA or RSA had a higher rate (13.5%) than patients without a previous surgery (5.4%). Readmission rates for TSA and RSA were virtually identical. Most readmissions were due to surgical (69.2%) rather than medical complications (30.8%). The most common reasons for readmission were surgical-site infection and deep vein thrombosis. There were no statistically significant differences between the baseline patient characteristics of readmitted and non-readmitted patients. However, the proportion of males (69.2%) was more than twice the one of females (30.8%) among readmitted patients. Conclusion: The readmission rate within 90 days after surgery was relatively low among patients who underwent either a TSA or RSA at our institution. Surgically related causes were largely responsible for readmissions.

Venous thromboembolism following surgical management of proximal humerus fractures: a systematic review

“…Twelve studies met the inclusion and exclusion criteria and were analyzed in this review. 1 , 3 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 19 , 22 , 32 Two were level II evidence, 11 , 32 3 were level III evidence, 6 , 10 , 19 and 7 were level IV evidence. 1 , 3 , 8 , 9 , 12 , 13 , 22 The total pooled number of shoulders with surgically treated PHFs was 18,240 in 18,238 patients.…”

“… 1 , 3 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 19 , 22 , 32 Two were level II evidence, 11 , 32 3 were level III evidence, 6 , 10 , 19 and 7 were level IV evidence. 1 , 3 , 8 , 9 , 12 , 13 , 22 The total pooled number of shoulders with surgically treated PHFs was 18,240 in 18,238 patients. This cohort had a mean age range of 55.7-72 years.…”

“… Study LOE No. of patients Mean age y ± SD, (range) Mean FU (mo) Shoulder arthroplasty Hemi RSA TSA ORIF Andres-Cano et al 1 IV 21 72 ± 6.8 26.3 ± 10.9 21 19 0 0 0 Chand et al 3 IV 21 NR 3 ∗ 21 0 21 0 0 Dillon et al 6 III 1045 72 ± 12 40.9 ± 27.9 1045 961 72 12 0 Heyer et al 8 IV 92 58.1 6 12 4 8 0 80 Hoxie et al 9 IV 137 63.1 NR 37 37 0 0 102 Imberti et al 10 III 28 55.65 3 ∗ 0 0 0 0 …”